411 results about "Pancreatic cancer cell" patented technology

The present invention is directed to an antigen found on the surface of rat and human pancreatic cancer cells and provides antibodies of high specificity and selectivity to this antigen as well as hybridomas secreting the subject antibodies. Methods for both the diagnosis and treatment of pancreatic cancer are also provided. This tissue marker of pancreatic adenocarcinoma, an approximately 43.5 kD surface membrane protein designated PaCa-Ag1, is completely unexpressed in normal pancreas but abundantly expressed in pancreatic carcinoma cells. Moreover, a soluble form of PaCa-Ag1 exists, having a molecular weight about 36 to about 38 kD, that is readily identified in sera and other body fluids of pancreatic cancer patients, using a subject antibody.

The present inventors discovered that neural invasion is suppressed by inhibiting IL-6 in a model for neural invasion of pancreatic cancer, and completed the present invention. The present inventors also demonstrated that: an IL-6 receptor is expressed in cells of human pancreatic cancer cell lines; and IL-6 enhances the chemotactic and migratory activities and intracellular signaling of pancreatic cancer cells; and thus pancreatic cancer can be treated by inhibiting IL-6. Furthermore, the present inventors found that neural invasion of human pancreatic cancer can be suppressed, from the results of administering IL-6 inhibitors to neural invasion model mice.

The present invention relates to a novel gene, CaSm, that is highly expressed in cancer tissues and cell lines, especially pancreatic cancer. The full length cDNA of CaSm encodes a protein of 133 amino acids. CaSm contains the two Sm motifs found in the common snRNP proteins, with the greatest homology to the Sm G protein (60% similarity). The present invention further encompasses CaSm peptides, fusion proteins, host cell expression systems, antibodies to CaSm, antisense CaSM molecules, and compounds that modulate CaSm gene expression or CaSm activity. Antisense CaSm RNA is able to alter the transformed phenotype of pancreatic cancer cells by reducing their ability to form large colonies in soft agar when compared to untransfected cells. The present invention also encompasses methods for disease diagnosis, drug screening and the treatment of cancer.

The invention provides a veratramine degradation product veratrum fluorene aldehyde 1 and derivatives thereof. The invention uses steroidal alkaloid veratramine (A) as raw material and prepares veratrum fluorene aldehyde by oxidative degradation of m-chloroperoxybenzoic acid to obtain 20 derivative compounds of the veratrum fluorene aldehyde 1 after further oxidation, reduction and condensation reaction. The 20 compounds of the invention have good inhibitory activity on cancer cells, wherein the compounds 1, 2, 5, 8, 13 and 17 have good inhibitory activity on cells of human pancreatic cancer cells BxPC-3 and SW1990, small-cell lung cancer cells NCI-H446, human colorectal cancer LOVO and the like, and the inhibitory activity of the compound veratrum fluorene aldehyde 1 is the most significant.

AnnexinA2 (ANXA2), a member of the Annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. AnnexinA2 is abundantly expressed in pancreatic adenocarcinomas and cell surface/membrane AnnexinA2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas. The cytoplasmic to cell surface translocation of AnnexinA2 expression is critical for pancreatic cancer cell invasion. In addition, phosphorylation of AnnexinA2 at Tyrosine 23 is important for its localization to the cell surface and for the invasion of pancreatic cancer cells. Finally, loss of AnnexinA2 leads to the loss of the Epithelial-Mesenchymal Transition.

The present invention relates to the use of cytoxicity based on the effector function of anti-EphA4 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-EphA4 antibody as an active ingredient for damaging EphA4-expressing cells using antibody effector function. Since EphA4 is strongly expressed in pancreatic cancer cells, the present invention is particularly useful in pancreatic cancer therapies.

The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of pancreatic cancer cells and be used as a pharmaceutical composition to inhibit the pancreatic tumor growth.

The invention belongs to the technical field of biology and relates to an early pancreatic cancer marker and a detection method thereof. A biological micromolecule which can be used for early pancreatic cancer molecular diagnosis and treatment is developed on the basis of expression intensity differences of various micro ribonucleic acids in early pancreatic cancer cells. The early pancreatic cancer marker has advantages of wide detection pedigree, high sensitivity, high specificity, low detection cost, convenience in material acquisition, easiness in sample storage and the like. The method can be widely applied to pancreatic cancer early screening and prognosis and the like, low specificity and low sensitivity due to hard-to-overcome individual differences caused by intrinsic instabilityof single markers or biomarkers clinically and extensively applied at present are improved, the early pancreatic cancer clinical detection rate is remarkably increased, the pancreatic cancer misdiagnosis rate and missed diagnosis rate are decreased, and the method is an effective means of early pancreatic cancer detection.

The invention relates to an anticancer medicine which is a lanosterol derivative. The compound has an anticancer effect, and can inhibit the growths of lung cancer cells, liver cells, mammary gland cells, brain cancer cells, and pancreatic cancer cells. The medicine is a compound with a general formula of (I), (II), (III), or (IV). The invention also provides an application of the compound or pharmaceutically acceptable salt thereof in preparing medicines used for treating cancers. The medicine can be used independently, and can be used in combination. Especially, the medicine can be used in combination with gemcitabine or nexavar. The medicine can be used in treating cancers such as lung cancer, liver cancer, pancreatic cancer, breast cancer, brain cancer, and the like.

A polypeptide M204C4 for suppressing the activity of gelatinase A (MMP-2) is composed of the amino acid sequence shown by HNWTRWLLHPDRGGGS is disclosed. It can also suppress the invasion and transfer of external pancreas cancer cells PANC01 and CFPAC-1. Its preparing process includes such steps as affinity screening and reproduction of bacteriophage several times to obtain the bacteriophage with specific binding to MMP-2, coating, cloning and monoclonal screening with fluorescent screening reagent kit.

This invention relates to a pharmaceutical composition for inhibiting the growth and/or metastasis of invasive pancreatic cancer in a subject, comprising a molecular-targeted anticancer agent and a pharmaceutically acceptable carrier, wherein the molecular-targeted anticancer agent is a conjugate of a toxin or cytotoxic agent and an antibody or fragment thereof which immunologically and specifically binds to a cell-surface folate receptor β (FRβ) protein of an FRβ (+) macrophage that exists around pancreatic cancer cells at the invasive front, and to a diagnostic agent and kit for determining the degree of malignancy of pancreatic cancer or the presence of invasive pancreatic cancer, characterized by determining that the cancer tissue is invasive and metastatic when FRβ (+) macrophage is distributed around pancreatic cancer cells at the invasive front.

Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells.

The invention belongs to the field of microorganism animal cell lines, and particularly relates to a pancreatic cancer cell line with lymphatic channel high migration activity. According to the pancreatic cancer cell line with the lymphatic channel high migration activity, a human pancreatic cancer BxPC-3 cell line is adopted as source cells, by means of a nude mouse palmula subcutaneous vaccinization method, lymphatic metastasis oncocyte sunlines with different migration potentialities are separated from matrilineal BxPC-3 cells, a pancreatic cancer cell line BxPC-3-LN with the lymphatic channel high migration activity is screened out through experiments inside and outside human bodies, a storage number is CGMCC NO.5421, and the storage date is October 28th, 2011. The pancreatic cancer cell line with the lymphatic channel high migration activity is the same as the matrilineal BxPC-3 cells in the genetic background, is characterized by being strong in invasiveness, high in migration efficiency and concentrated in migration, provides a suitable experimental platform for research on pancreatic cancer migration mechanism and the screening of antineoplastic drugs, and has very important significance and wide application prospects.

The invention discloses a tetrandrine derivative with antitumor activity and a preparation method thereof. The structural formula of the compound is shown in the specification. The preparation method comprises the following steps: dissolving bisbenzylisoquinoline compound serving as raw material in certain solvent; adding an alkali reagent and a reactant Y, and mixing; reacting for 0.1 to 72 hours under temperature of -20 to 300 DEG C; neutralizing the reacted solution with acid, and then separating and purifying to prepare the objective product. The tetrandrine derivative prepared by the invention can well inhibit proliferation of human hepatoma cell line HepG2 and pancreatic cancer cell SW1990, and can be used for preparing antitumor medicines.

The present invention relates to a method for inhibiting tumor growth, in particular to the method using dehydrosulphurenic acid to inhibit the growth of leukemia cell or pancreatic cancer cell by a compound extracted and purified from Antrodia cinnamomea. Dehydrosulphurenic acid of the invention can be used as a pharmaceutical composition to inhibit the tumor growth of leukemia or pancreatic cancer.